相似文献
1
Strategies to improve outcomes of autologous hematopoietic cell transplant in lymphoma.
Bone Marrow Transplant. 2019 Jul;54(7):943-960. doi: 10.1038/s41409-018-0378-z. Epub 2018 Nov 2.
2
Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.
Biol Blood Marrow Transplant. 2015 Jun;21(6):1046-1053. doi: 10.1016/j.bbmt.2015.02.005. Epub 2015 Feb 14.
3
Early Toxicity and Efficacy of Four Different Conditioning Regimens for Autologous Hematopoietic Cell Transplantation in Patients With Lymphoma: Impact of Drug Shortages in a Resource-Constrained Country.
Transplant Cell Ther. 2024 Oct;30(10):1003.e1-1003.e9. doi: 10.1016/j.jtct.2024.07.025. Epub 2024 Aug 2.
4
Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Biol Blood Marrow Transplant. 2016 Dec;22(12):2155-2158. doi: 10.1016/j.bbmt.2016.08.026. Epub 2016 Aug 26.
5
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
Biol Blood Marrow Transplant. 2016 Jul;22(7):1197-1205. doi: 10.1016/j.bbmt.2016.03.018. Epub 2016 Mar 31.
6
Prognostic differences between carmustine, etoposide, cytarabine and melphalan (BEAM) and carmustine, etoposide, cytarabine, melphalan and fludarabine (BEAMF) regimens before autologous stem cell transplantation plus chimeric antigen receptor T therapy in patients with refractory/relapsed B-cell non-Hodgkin-lymphoma.
Cytotherapy. 2024 May;26(5):456-465. doi: 10.1016/j.jcyt.2024.01.012. Epub 2024 Feb 19.
7
Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma.
Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):417-23. doi: 10.1016/j.clml.2013.03.009. Epub 2013 Jun 15.
8
Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma.
Clin Lymphoma Myeloma Leuk. 2018 Apr;18(4):272-279. doi: 10.1016/j.clml.2018.02.008. Epub 2018 Feb 15.
9
Gemcitabine-based conditioning compared to BEAM/BEAC conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: No difference in outcomes.
Cancer Med. 2024 Jan;13(2):e6965. doi: 10.1002/cam4.6965.
10
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi.
Biol Blood Marrow Transplant. 2018 Sep;24(9):1814-1822. doi: 10.1016/j.bbmt.2018.05.018. Epub 2018 May 29.
引用本文的文献
1
Abnormally high expression of CHI3L1 in peripheral blood mononuclear cells and serum and their potential diagnosis and prediction from lymphoma patients.
Front Immunol. 2025 Apr 7;16:1557802. doi: 10.3389/fimmu.2025.1557802. eCollection 2025.
2
Women's Sexual Dysfunctions Following Stem Cell Transplant and the Impact on Couple Relationship.
Life (Basel). 2023 Dec 25;14(1):35. doi: 10.3390/life14010035.
3
A pilot study of cord blood-derived natural killer cells as maintenance therapy after autologous hematopoietic stem cell transplantation.
Ann Hematol. 2023 Nov;102(11):3229-3237. doi: 10.1007/s00277-023-05471-4. Epub 2023 Sep 29.
4
[A comparison of C+SCAV and SEAM conditioning regimens in efficacy and safety in autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma patients].
Zhonghua Xue Ye Xue Za Zhi. 2022 Aug 14;43(8):668-673. doi: 10.3760/cma.j.issn.0253-2727.2022.08.009.
5
Population Pharmacokinetics of Melphalan in a Large Cohort of Autologous and Allogeneic Hematopoietic Cell Transplantation Recipients: Towards Individualized Dosing Regimens.
Clin Pharmacokinet. 2022 Apr;61(4):553-563. doi: 10.1007/s40262-021-01093-z. Epub 2021 Dec 2.
6
Abnormal body composition is a predictor of adverse outcomes after autologous haematopoietic cell transplantation.
J Cachexia Sarcopenia Muscle. 2020 Aug;11(4):962-972. doi: 10.1002/jcsm.12570. Epub 2020 Mar 25.
本文引用的文献
1
A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma.
Am J Hematol. 2020 Jul;95(7):775-783. doi: 10.1002/ajh.25818. Epub 2020 Apr 22.
2
Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation.
J Hematol Oncol. 2018 Jun 28;11(1):87. doi: 10.1186/s13045-018-0631-3.
3
High-dose therapy with BEAC conditioning compared to BEAM conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: no differences in toxicity or outcome. A matched-control study of the EBMT-Lymphoma Working Party.
Bone Marrow Transplant. 2018 Dec;53(12):1553-1559. doi: 10.1038/s41409-018-0196-3. Epub 2018 Jun 8.
4
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi.
Biol Blood Marrow Transplant. 2018 Sep;24(9):1814-1822. doi: 10.1016/j.bbmt.2018.05.018. Epub 2018 May 29.
5
Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study.
Br J Haematol. 2018 May;181(3):341-349. doi: 10.1111/bjh.15184. Epub 2018 Apr 2.
6
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
Biol Blood Marrow Transplant. 2018 Aug;24(8):1602-1609. doi: 10.1016/j.bbmt.2018.02.020. Epub 2018 Mar 2.
7
Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma.
Clin Lymphoma Myeloma Leuk. 2018 Apr;18(4):272-279. doi: 10.1016/j.clml.2018.02.008. Epub 2018 Feb 15.
8
Updated Results of Rituximab Pre- and Post-BEAM with or without Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma.
Clin Cancer Res. 2018 May 15;24(10):2304-2311. doi: 10.1158/1078-0432.CCR-17-3561. Epub 2018 Feb 23.
9
Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers.
Am J Hematol. 2018 Jun;93(6):729-735. doi: 10.1002/ajh.25077. Epub 2018 Mar 14.
10
Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703).
Biol Blood Marrow Transplant. 2018 Apr;24(4):700-707. doi: 10.1016/j.bbmt.2017.12.798. Epub 2017 Dec 28.
Zotero 插件